|D053717||Pneumonia, Ventilator-Associated NIH||0.33|
|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI. Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections. We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.
Description: days without ventilation support during 28 days after patients' enrollmentMeasure: Ventilation-free days Time: on the day 28 after enrollment
Description: wether the patient survivesMeasure: 28-days mortality Time: on the day 28 after enrollment
Description: days of the patients staying in the ICUMeasure: ICU length of stay Time: on the day 28 after enrollment
Description: the rate of CPRMeasure: Demand for first aid measuments Time: on the day 28 after enrollment
Description: days of using vasopressorsMeasure: Vasopressor days Time: on the day 28 after enrollment
Description: P O2/Fi O2 which reflects patients' respiratory functionMeasure: Respiratory indexes Time: on the day 10 and 28 after enrollment
Description: Ecmo or ventilatorMeasure: Ventilator parameters Time: on the day 10 and 28 after enrollment
Description: Acute Physiology and Chronic Health EvaluationMeasure: APACHE II scores Time: on the day 10 after enrollment
Description: Sepsis-related Organ Failure AssessmentMeasure: SOFA scores Time: on the day 10 after enrollment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports